This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swisher, E. M. Articles by Taniguchi, T. Search for Related Content PubMed PubMed Citation Articles by Swisher, E. M. Articles by Taniguchi, T.

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

Departments of ¹ Obstetrics and Gynecology and ² Medicine, University of Washington; Divisions of ³ Human Biology and ⁴ Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; and ⁵ Cedars-Sinai Medical Center, Women's Cancer Research Institute, Los Angeles, California

Requests for reprints: Toshiyasu Taniguchi, Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, C1-015, Seattle, WA 98109-1024. Phone: 206-667-7283; Fax: 206-667-5815; E-mail: ttaniguc{at}fhcrc.org.

Key Words: DNA damage and repair mechanisms • BRCA1 • BRCA2 • cisplatin • drug resistance

Although ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance. Previously, we showed that acquired resistance to cisplatin in BRCA2-mutated tumors can be mediated by secondary intragenic mutations in BRCA2 that restore the wild-type BRCA2 reading frame. Here, we show that secondary mutations of BRCA1 also occur in BRCA1-mutated ovarian cancer with platinum resistance. We evaluated nine recurrent BRCA1-mutated ovarian cancers previously treated with platinum compounds, including five with acquired platinum resistance, one with primary platinum resistance, and three with platinum sensitivity. Four of the six recurrent platinum-resistant tumors had developed secondary genetic changes in BRCA1 that restored the reading frame of the BRCA1 protein, whereas none of the three platinum-sensitive recurrent tumors developed BRCA1 sequence alterations. We immunohistochemically confirmed restored expression of BRCA1 protein in two cases with secondary mutations. Intriguingly, the case with primary platinum resistance showed back mutation of BRCA1 in the primary tumor and showed another secondary mutation in the recurrent tumor. Our results suggest that secondary mutations in BRCA1 can mediate resistance to platinum in BRCA1-mutated ovarian tumors. [Cancer Res 2008;68(8):2581–6]

This article has been cited by other articles:

				J. M.-M. Kwok, B. Peck, L. J. Monteiro, H. D.C. Schwenen, J. Millour, R. C. Coombes, S. S. Myatt, and E. W.-F. Lam FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells Mol. Cancer Res., January 1, 2010; 8(1): 24 - 34. [Abstract] [Full Text] [PDF]

				W. Sakai, E. M. Swisher, C. Jacquemont, K. V. Chandramohan, F. J. Couch, S. P. Langdon, K. Wurz, J. Higgins, E. Villegas, and T. Taniguchi Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma Cancer Res., August 15, 2009; 69(16): 6381 - 6386. [Abstract] [Full Text] [PDF]

				M. Kriege, C. Seynaeve, H. Meijers-Heijboer, J. M. Collee, M. B.E. Menke-Pluymers, C. C.M. Bartels, M. M.A. Tilanus-Linthorst, J. Blom, E. Huijskens, A. Jager, et al. Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers J. Clin. Oncol., August 10, 2009; 27(23): 3764 - 3771. [Abstract] [Full Text] [PDF]

				J. D. Iglehart and D. P. Silver Synthetic Lethality -- A New Direction in Cancer-Drug Development N. Engl. J. Med., July 9, 2009; 361(2): 189 - 191. [Full Text] [PDF]

				V. L. Giranda and A. Shoemaker From Concept to Clinical Trials: Evaluation of Poly (ADP-Ribose) Polymerase Inhibitor Preclinical Data and Its Use in the Design of Clinical Trials Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 51 - 56. [Full Text] [PDF]

				J. Fasano and F. Muggia Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development Ann. Onc., April 1, 2009; 20(4): 609 - 614. [Abstract] [Full Text] [PDF]

				J. M. Saunus, J. D. French, S. L. Edwards, D. J. Beveridge, E. C. Hatchell, S. A. Wagner, S. R. Stein, A. Davidson, K. J. Simpson, G. D. Francis, et al. Posttranscriptional Regulation of the Breast Cancer Susceptibility Gene BRCA1 by the RNA Binding Protein HuR Cancer Res., November 15, 2008; 68(22): 9469 - 9478. [Abstract] [Full Text] [PDF]

				S. Rottenberg, J. E. Jaspers, A. Kersbergen, E. van der Burg, A. O. H. Nygren, S. A. L. Zander, P. W. B. Derksen, M. de Bruin, J. Zevenhoven, A. Lau, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs PNAS, November 4, 2008; 105(44): 17079 - 17084. [Abstract] [Full Text] [PDF]